In This Article:
BORDEAUX, France, May 06, 2025--(BUSINESS WIRE)--Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Tuesday, May 27, 2025, at 2 p.m., at 1 rue Lafaurie de Monbadon, 33000 Bordeaux.
The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the Bulletin des Annonces Légales Obligatoires "BALO" on April 18, 2025 (bulletin number 47).
Shareholders who are unable to attend the meeting in person, may exercise their voting rights remotely, before the general meeting:
-
either by sending a proxy to the Company,
-
or by voting by mail,
At this purpose, shareholders shall use the form available on www.aelisfarma.com in accordance with the procedures indicated in the notice of meeting published on April 18, 2025, in the BALO.
All documents relating to this General Meeting are available on request from the Company or can be consulted on the Company's website under the heading Investors / General Meetings.
In accordance with the applicable legal and regulatory provisions:
-
any registered shareholder may, up to and including the fifth day before the general meeting, request that the Company send him the documents provided for in Articles L. 225-115 and R. 225-83 of the Commercial Code. In the event of an express request, such documents may be sent by electronic means. For holders of bearer shares, the exercise of this right is subject to the provision by their authorized intermediary of a certificate of account registration;
-
any shareholder may consult the documents referred to in Articles L. 225-115 and R. 225-83 of the Commercial Code at the company's registered office.
Shareholders wishing to follow the meeting but unable to attend in person are invited to connect via the following link: click here.
This live webcast will only be in French and will not allow remote voting or questions.
A recording of the Meeting will be available on the Company's website (www.aelisfarma.com) no later than seven (7) business days after the date of the Meeting.
***
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company’s CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.